Señales en vivo de 1099.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 04:08):

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China...

Stats
Volumen de hoy	18.07M
Volumen promedio	5.10M
Capitalización de mercado	63.00B
EPS	HKD0 ( 2024-04-25 )
Last Dividend	HKD0.901 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	6.45
ATR14	HKD0.0460 (0.23%)

Volumen Correlación

Largo: 0.09 (neutral)

Corto: -0.43 (neutral)

Signal:(45.299) Neutral

SINOPHARM GROUP CO LTD Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SINOPHARM GROUP CO LTD Correlación - Moneda/Commodity

-0.04
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.29
( neutral )

-0.61
( weak negative )

0.05
( neutral )

SINOPHARM GROUP CO LTD Finanzas

Annual	2023
Ingresos:	HKD596.57B
Beneficio Bruto:	HKD48.51B (8.13 %)
EPS:	HKD2.90

FY	2023
Ingresos:	HKD596.57B
Beneficio Bruto:	HKD48.51B (8.13 %)
EPS:	HKD2.90

FY	2022
Ingresos:	HKD552.15B
Beneficio Bruto:	HKD47.43B (8.59 %)
EPS:	HKD4.60

FY	2021
Ingresos:	HKD521.05B
Beneficio Bruto:	HKD44.05B (8.45 %)
EPS:	HKD2.49

Financial Reports:

No articles found.

SINOPHARM GROUP CO LTD Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.901 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

SINOPHARM GROUP CO LTD Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.69 - good (96.91%) | Divividend Growth Potential Score: 3.37 - Decrease likely (32.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0101	2010-04-29
Last Dividend	HKD0.901	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	14	--
Total Paid Out	HKD6.94	--
Avg. Dividend % Per Year	0.00%	--
Score	2.6	--
Div. Sustainability Score	9.69
Div.Growth Potential Score	3.37
Div. Directional Score	6.53	--

Next Divdend (Est)
(2025-04-07)

HKD0.958 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2270.HK	Ex Dividend Junior	2023-06-26	Insufficient data to determine frequency	0.00%
1263.HK	Ex Dividend Junior	2023-09-14	Annually	0.00%
0321.HK	Ex Dividend Knight	2023-08-31	Semi-Annually	0.00%
6033.HK	Ex Dividend Knight	2023-09-19	Semi-Annually	0.00%
1818.HK	Ex Dividend Junior	2023-06-07	Annually	0.00%
0848.HK	Ex Dividend Junior	2023-05-24	Annually	0.00%
0006.HK	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
2588.HK	Ex Dividend Knight	2023-09-25	Semi-Annually	0.00%
1382.HK	Ex Dividend Knight	2023-08-15	Semi-Annually	0.00%
0455.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0155	1.500	9.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0358	1.200	8.81	10.00	[0 - 0.3]
returnOnEquityTTM	0.194	1.500	8.96	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.395	0.800	8.03	6.42	[1 - 3]
quickRatioTTM	1.034	0.800	8.63	6.90	[0.8 - 2.5]
cashRatioTTM	0.264	1.500	9.64	10.00	[0.2 - 2]
debtRatioTTM	0.188	-1.500	6.87	-10.00	[0 - 0.6]
interestCoverageTTM	20.69	1.000	3.45	3.45	[3 - 30]
operatingCashFlowPerShareTTM	23.49	2.00	2.17	4.34	[0 - 30]
freeCashFlowPerShareTTM	22.23	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.965	-1.500	6.14	-9.21	[0 - 2.5]
grossProfitMarginTTM	0.0838	1.000	-1.937	-1.937	[0.2 - 0.8]
operatingProfitMarginTTM	0.0381	1.000	-1.238	-1.238	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.017	1.000	5.46	5.46	[0.2 - 2]
assetTurnoverTTM	2.31	0.800	10.00	8.00	[0.5 - 2]
Total Score				9.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.31	1.000	9.67	0	[1 - 100]
returnOnEquityTTM	0.194	2.50	9.33	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	22.23	2.00	2.59	10.00	[0 - 30]
dividendYielPercentageTTM	4.75	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	23.49	2.00	2.17	4.34	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0825	1.000	-0.437	0	[0.1 - 0.5]
Total Score				3.37

SINOPHARM GROUP CO LTD

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.